Brief: Agenus Receives Fast Track Designation For Botensilimab And Balstilimab In Colorectal Cancer
17/04/2023 13:38
April 17 (Reuters) - Agenus Inc AGEN.O :
* AGENUS RECEIVES FAST TRACK DESIGNATION FOR BOTENSILIMAB
AND
BALSTILIMAB IN COLORECTAL CANCER
Source text for Eikon: ID:nBw1zrt0Xa
Further company coverage: AGEN.O
Recent news on Agenus
See all newsBrief: Agenus Reports 72% Of Patients With Locally Advanced Dmmr Colon Cancer Had No Cancer Remaining At Surgery Following Six Weeks Of Bot+Bal In Phase 2 Neoasis Study At Esmo 2026
Brief: Armenia Grants First Marketing Authorizations For Agenus’ Bot+Bal In Previously Treated Mss Metastatic Colorectal Cancer
Brief: Agenus - Unit Enters Second Loan Modification Agreement With Ocean 1181 On Aug 12, 2026 - SEC Filing
Agenus Inc reports results for the quarter ended June 30 - Earnings Summary
Agenus Q2 revenue rises on access and royalty income